BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 27365460)

  • 1. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.
    Styczynski J; van der Velden W; Fox CP; Engelhard D; de la Camara R; Cordonnier C; Ljungman P;
    Haematologica; 2016 Jul; 101(7):803-11. PubMed ID: 27365460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y; Chen J; Wu D
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation.
    Liu L; Zhang X; Feng S
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1341-1349. PubMed ID: 29530767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice.
    Jiménez S
    Clin J Oncol Nurs; 2015 Feb; 19(1):94-8. PubMed ID: 25689655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus and Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation.
    Tsao SY; Chang KC; Chen YP; Yeh YM; Su WC; Chen TY
    Ann Hematol; 2011 Jan; 90(1):113-4. PubMed ID: 20369358
    [No Abstract]   [Full Text] [Related]  

  • 8. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Transplantation Lymphoproliferative Disorders in Adults.
    Dierickx D; Habermann TM
    N Engl J Med; 2018 Feb; 378(6):549-562. PubMed ID: 29414277
    [No Abstract]   [Full Text] [Related]  

  • 12. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention?
    Bakker NA; van Imhoff GW
    Haematologica; 2007 Nov; 92(11):1447-50. PubMed ID: 18024391
    [No Abstract]   [Full Text] [Related]  

  • 14. [Recent advances on diagnosis and therapy of lymphoproliferative disorders after allo-HSCT].
    Gu B; Chen GH; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):538-42. PubMed ID: 24763039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders.
    Singavi AK; Harrington AM; Fenske TS
    Cancer Treat Res; 2015; 165():305-27. PubMed ID: 25655616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Focused Review of Epstein-Barr Virus Infections and PTLD in Pediatric Transplant Recipients: Guidance From the IPTA and ECIL Guidelines.
    Yamada M; L'Huillier AG; Green M
    J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S31-S38. PubMed ID: 38417085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of post-transplant lymphoproliferative disorders.
    Llaurador G; McLaughlin L; Wistinghausen B
    Curr Opin Pediatr; 2017 Feb; 29(1):34-40. PubMed ID: 27906865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Post-Transplant Lymphoproliferative Disorders.
    Aghsaeifard Z; Alizadeh R
    Cardiovasc Hematol Disord Drug Targets; 2022; 22(2):96-103. PubMed ID: 35927798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
    Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
    Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.